Insider Buying: Cosmos Health (NASDAQ:COSM) CEO Acquires $69,965.00 in Stock

Cosmos Health Inc. (NASDAQ:COSM) CEO Grigorios Siokas acquired 349,825 shares of the stock in a transaction dated Thursday, July 30th. The stock was bought at an average price of $0.20 per share, with a total value of $69,965.00. Following the purchase, the chief executive officer directly owned 14,597,917 shares in the company, valued at $2,919,583.40. This represents a 2.46% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Grigorios Siokas also recently made the following trade(s):

• On Wednesday, July 29th, Grigorios Siokas bought 766,284 shares of Cosmos Health stock. The shares were bought at an average cost of $0.18 per share, for a total transaction of $137,931.12.
• On Thursday, June 11th, Grigorios Siokas bought 218,447 shares of Cosmos Health stock. The shares were bought at an average cost of $0.21 per share, for a total transaction of $45,873.87.
• On Wednesday, June 10th, Grigorios Siokas purchased 701,447 shares of Cosmos Health stock. The stock was bought at an average price of $0.23 per share, with a total value of $161,332.81.

Cosmos Health Stock Performance

COSM opened at $0.22 on Monday. Cosmos Health Inc. has a 1-year low of $0.16 and a 1-year high of $1.32. The company has a current ratio of 1.08, a quick ratio of 0.92 and a debt-to-equity ratio of 0.31. The company has a market cap of $12.94 million, a P/E ratio of -0.34 and a beta of 4.80. The company has a fifty day moving average price of $0.23 and a two-hundred day moving average price of $0.33.

Cosmos Health (NASDAQ:COSM) last announced its quarterly earnings data on Wednesday, May 20th. The company reported ($0.06) earnings per share for the quarter, meeting the consensus estimate of ($0.06). The firm had revenue of $18.40 million for the quarter, compared to analyst estimates of $17.93 million. Cosmos Health had a negative net margin of 30.41% and a negative return on equity of 52.85%. Analysts predict that Cosmos Health Inc. will post 0.01 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Separately, Weiss Ratings raised Cosmos Health from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company has a consensus rating of “Sell”.

Hedge Funds Weigh In On Cosmos Health

Several large investors have recently bought and sold shares of COSM. XTX Topco Ltd raised its holdings in shares of Cosmos Health by 52.1% in the fourth quarter. XTX Topco Ltd now owns 99,610 shares of the company’s stock valued at $50,000 after purchasing an additional 34,117 shares during the last quarter. Renaissance Technologies LLC grew its position in Cosmos Health by 16.7% in the 1st quarter. Renaissance Technologies LLC now owns 390,500 shares of the company’s stock worth $124,000 after purchasing an additional 55,925 shares in the last quarter. Finally, Citadel Advisors LLC grew its position in Cosmos Health by 133.1% in the 3rd quarter. Citadel Advisors LLC now owns 225,507 shares of the company’s stock worth $250,000 after purchasing an additional 128,776 shares in the last quarter. 12.61% of the stock is currently owned by institutional investors.

Cosmos Health Company Profile

Cosmos Health Inc manufactures, develops, and trades branded nutraceutical products in Greece, the United Kingdom, Croatia, Bulgaria, Cayman Islands, and Cyprus. It offers medicines, OTC medicines, nutraceutical products, vitamins, minerals and dietary, health care products, medical devices, baby products, and others under the Sky Premium Life and Mediterranation brand names. The company serves wholesale distributors and other healthcare providers, such as clinics, government agencies, independent retail and specialty pharmacies and independent specialty distributors.